PALO ALTO, Calif., Sept. 06, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, ...
- Based on these findings, BridgeBio intends to initiate a registrational clinical study of encaleret, an orally-administered investigational therapy, in chronic hypoparathyroidism in 2026 PALO ALTO, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback